This may be the higher the uptake of PSMA in prostatic lesions, the higher the malignancy of the lesions, resulting in an increased risk of bone or lymph node metastasis (25). The gene discussed is FOLH1; the disease is metastatic malignant neoplasm in the lymph nodes.